A Phase 3 interventional study of ranibizumab and aflibercept injection (VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Regeneron Pharmaceuticals. Completed at 188 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-12-28.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 67 studies testing aflibercept in Macular Degeneration, this one is the 2nd largest by enrollment, is the only one that started in 2007, is one of 18 in phase 3, and was the 4th registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Honghua Yu,MD
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 28
First in 2005; this study’s year is marked. 1 started in 2007.
This study's enrollment of 1,217 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 54 across the 67 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 67 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
17 studies in Macular Degeneration by Regeneron Pharmaceuticals: 2 open now, 3 under way, 2 of them phase 3. Of 14 finished, 9 (64%) have results posted.
Among the 17 studies in Macular Degeneration by Regeneron Pharmaceuticals, this one has the largest enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2007, is one of 5 in phase 3, and was the 4th registered.
Regeneron Pharmaceuticals’s Macular Degeneration studies by the year they started, since 2005.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 67 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Regeneron Pharmaceuticals’s 17 in Macular Degeneration:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a phase 3, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in the US and Canada.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Key
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ranibizumab
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Also known as: Lucentis
Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Also known as: VEGF Trap-Eye, BAY86-5321
Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Also known as: VEGF Trap-Eye, BAY86-5321
Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Also known as: VEGF Trap-Eye, BAY86-5321
Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)
Defined "maintenance of vision" as patients who lost fewer than 15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score compared to baseline.
Time frame: Baseline and at week 52
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning.
Time frame: Baseline and at week 52
Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF.
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning.
Time frame: Baseline and at week 52
Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
Time frame: Baseline and at Week 52
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF)
CNV area values measured in square millimeters (mm\^2); lower values represent better outcomes.
Time frame: Baseline and at week 52
The study was conducted at 164 sites in the United States and Canada. Recruitment period: 02 Aug 2007 to 15 Sep 2009.
| Milestone | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 |
|---|---|---|---|---|
| Started | 306 | 304 | 304 | 303 |
| Patients received treatment (saf) | 304 | 304 | 304 | 303 |
| Full analysis set (fas) population | 304 | 304 | 301 | 301 |
| Per protocol set (pps) population | 269 | 285 | 270 | 265 |
| Completed | 284 | 293 | 277 | 276 |
| Not completed | 22 | 11 | 27 | 27 |
| Withdrew: Adverse event | 4 | 3 | 5 | 4 |
| Withdrew: Death | 3 | 1 | 2 | 7 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 4 | 4 |
| Withdrew: Other | 1 | 0 | 4 | 1 |
| Withdrew: Protocol violation | 3 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 10 | 5 | 7 | 8 |
Defined "maintenance of vision" as patients who lost fewer than 15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score compared to baseline.
| percentage of patients | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | 94.4 ± 0 | 95.1 ± 0 | 95.9 ± 0 | 95.1 ± 0 | 95.1 ± 0 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning.
| letters read | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF | 8.1 ± 15.25 | 10.9 ± 13.77 | 6.9 ± 13.41 | 7.9 ± 15.00 | 8.5 ± 14.44 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity of: letter score of 73 to 25 (20/40 to 20/320) in the study eye; a higher score represents better functioning.
| percentage of patients | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF. | 30.9 ± 0 | 37.5 ± 0 | 24.9 ± 0 | 30.6 ± 0 | 31.1 ± 0 |
The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.
| scores on a scale | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF | 4.9 ± 14.01 | 6.7 ± 13.50 | 4.5 ± 11.87 | 5.1 ± 14.74 | 5.3 ± 13.59 |
CNV area values measured in square millimeters (mm\^2); lower values represent better outcomes.
| mm^2 | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF) | -4.2 ± 5.59 | -4.6 ± 5.47 | -3.5 ± 5.27 | -3.4 ± 6.02 | -3.9 ± 5.61 |
Collected over AEs reported from Day 1 to Wk 96. Yr 1 of tx (Day 1 to Wk 52): 21-day screening period followed by administration of study drug every 4 or 8 wks including sham injections at interim study visits (when study drug was not administered) for 48 wks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5mg Q4 | — | 94/304 (30.9%) | 261/304 (85.9%) |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | — | 70/304 (23%) | 254/304 (83.6%) |
| IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | — | 88/304 (28.9%) | 262/304 (86.2%) |
| IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | — | 90/303 (29.7%) | 258/303 (85.1%) |
| Event | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 |
|---|---|---|---|---|
| FALLInjury, poisoning and procedural complications | 8/304 | 13/304 | 7/304 | 16/303 |
| PNEUMONIAInfections and infestations | 14/304 | 6/304 | 5/304 | 8/303 |
| CARDIAC FAILURE CONGESTIVEEar and labyrinth disorders | 4/304 | 2/304 | 4/304 | 8/303 |
| ATRIAL FIBRILLATIONEar and labyrinth disorders | 3/304 | 2/304 | 7/304 | 7/303 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 0/304 | 3/304 | 7/304 | 5/303 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 3/304 | 3/304 | 6/304 | 6/303 |
| CORONARY ARTERY DISEASEEar and labyrinth disorders | 5/304 | 0/304 | 6/304 | 1/303 |
| MYOCARDIAL INFARCTIONEar and labyrinth disorders | 6/304 | 1/304 | 5/304 | 2/303 |
| CEREBROVASCULAR ACCIDENTNervous system disorders | 2/304 | 3/304 | 1/304 | 5/303 |
| SQUAMOUS CELL CARCINOMA OF Skin and subcutaneous tissue disordersNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/304 | 3/304 | 2/304 | 4/303 |
| Event | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 |
|---|---|---|---|---|
| VITREOUS FLOATERSEye disorders | 47/304 | 49/304 | 30/304 | 29/303 |
| NASOPHARYNGITISInfections and infestations | 36/304 | 46/304 | 41/304 | 39/303 |
| RETINAL HAEMORRHAGEEye disorders | 43/304 | 36/304 | 36/304 | 22/303 |
| Eye disorders PAINEye disorders | 34/304 | 39/304 | 35/304 | 31/303 |
| HYPERTENSIONVascular disorders | 35/304 | 30/304 | 32/304 | 33/303 |
| VISUAL ACUITY REDUCEDEye disorders | 27/304 | 10/304 | 20/304 | 19/303 |
| UPPER RESPIRATORY TRACT Infections and infestationsIONInfections and infestations | 18/304 | 18/304 | 19/304 | 26/303 |
| URINARY TRACT Infections and infestationsIONInfections and infestations | 26/304 | 22/304 | 25/304 | 23/303 |
| VITREOUS DETACHMENTEye disorders | 16/304 | 24/304 | 25/304 | 24/303 |
| BRONCHITISInfections and infestations | 23/304 | 19/304 | 16/304 | 24/303 |
| Age Continuous(years) | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Mean | 78.2 ± 7.59 | 77.7 ± 7.93 | 78.3 ± 8.10 | 77.9 ± 8.39 | 78.0 ± 8.00 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Female | 172 | 194 | 169 | 179 | 714 |
| Male | 132 | 110 | 135 | 124 | 501 |
| Ethnicity (NIH/OMB)(Participants) | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 7 ± 0 | 11 ± 0 | 11 ± 0 | 12 ± 0 | 41 |
| Not Hispanic or Latino | 297 | 293 | 293 | 291 | 1174 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 ± 0 | 0 ± 0 | 2 ± 0 | 1 ± 0 | 5 |
| Asian | 0 ± 0 | 3 ± 0 | 5 ± 0 | 4 ± 0 | 12 |
| Native Hawaiian or Other Pacific Islander | 1 ± 0 | 0 ± 0 | 0 ± 0 | 1 ± 0 | 2 |
| Black or African American | 1 ± 0 | 1 ± 0 | 0 ± 0 | 1 ± 0 | 3 |
| White | 296 ± 0 | 295 ± 0 | 294 ± 0 | 289 ± 0 | 1174 |
| More than one race | 0 ± 0 | 0 ± 0 | 0 ± 0 | 1 ± 0 | 1 |
| Unknown or Not Reported | 4 ± 0 | 5 ± 0 | 3 ± 0 | 6 ± 0 | 18 |
| Baseline National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score(scores on a scale) | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Mean | 71.7 ± 17.29 | 70.4 ± 16.60 | 71.1 ± 17.72 | 69.5 ± 16.82 | 70.7 ± 17.11 |
| Baseline Area of Choroidal Neovascularization (CNV)(mm^2) | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Mean | 6.52 ± 5.245 | 6.59 ± 5.052 | 6.49 ± 4.437 | 6.56 ± 5.129 | 6.54 ± 4.968 |
| Baseline Lesion Type(patients) | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Occult | 115 ± 0 | 110 ± 0 | 123 ± 0 | 118 ± 0 | 466 |
| Minimally Classic | 101 ± 0 | 105 ± 0 | 97 ± 0 | 112 ± 0 | 415 |
| Predominantly Classic | 82 ± 0 | 87 ± 0 | 82 ± 0 | 71 ± 0 | 322 |
| Missing | 6 ± 0 | 2 ± 0 | 2 ± 0 | 2 ± 0 | 12 |
| Baseline Total Lesion Size(mm^2) | Ranibizumab 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | IAI (EYLEA, VEGF Trap-Eye) 2.0mg Q8 | Total |
|---|---|---|---|---|---|
| Mean | 6.99 ± 5.491 | 6.98 ± 5.388 | 6.96 ± 4.711 | 6.88 ± 5.214 | 6.95 ± 5.202 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 188 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Aug 2007, a primary completion of Sep 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 7 months after primary completion. A results delay was requested in Jan 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept